Τόμος 8 (1990) – Τεύχος 3 – Άρθρο 6 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 8 (1990) – Issue 3 – Article 6 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

8: 175-179 (1990)

PHARMAKON-Press: Epitheorese Klin. Farmakol. Farmakokinet.

8: 175-179 (1990)

Vancomycin hydrochloride is a unique glycopeptide antibiotic structurally unrelated to our currently available antibiotics. It is the antibiotic of choice in the treatment of serious infections due to methicillin-resistant Staphylococcus aureus and Staphylococcus e­pidermidis. The usage of vancomycin has increased markedly during the last ten years. Reported adverse reactions attributed to van­comycin have included hematuria, proteinuria and azotemia. Until now 58 cases of vanco­mycin associated nephrotoxicity have been reported in the Literature. Many of these patients also had pre-existing renal dysfunction or were concomitantly receiving other nephro­toxic agents. The exact incidence of nephroto­xicity is uncertain, but is probably less than with the current relatively pure product. The correlation of nephrotoxicity with certain serum vancomycin concentrations remains to be cla­rified. The widely accepted of vancomycin serum concentrations range from 30 to 40 μg/L. In addition, the concomitant use of other potentially nephrotoxic agents should be avoi­ded.

1. Καραχάλιος, Γ.N.: Κλινικός Οδηγός Αντιμικροβιακής Θεραπίας. Αθήνα, 1980
2. Καραχάλιος, Γ.N., Γεωργιόπουλος, Α.N.: Θεραπεία των λοιμώξεων σε ασθενείς με αλλεργία στην πενικιλλίνη. Mat. Med. Greca (Υπό Δημοσίευση)
3. Cheung, P.R.F., Dipiro, J.T.: Vancomycin: an update. Pharmacοtherapy 6: 153 (1986)
4. Neihart, R.E., Fried, J.S., Hodges, G.R.: Coagulase-negative staphylocοcci. South Med. J. 81: 491 (1988)
5. Young, E.J., Sugarman, B.: Infections in prosthetic devi­ces. Surg. Clin. North Am. 68: 167 (1988)